Consensus EPS · Q2 2026
-$7.27
Consensus revenue · Q2 2026
$7.4B
Analysts
13
Expected report
Aug 4, 2026
What to watch
- Analyst ratings: Mixed
Analyst consensus
Based on estimates from 13 analysts.
| Metric | Low | Consensus | High |
|---|---|---|---|
| Revenue | $7.2B | $7.4B | $7.5B |
| EPS | -$7.93 | -$7.27 | -$6.40 |
| EBITDA | $2.5B | $2.6B | $2.6B |
| EBIT | $1.9B | $1.9B | $1.9B |
| Net income | -$9.4B | -$9.1B | -$9B |
- Revenue$7.4B
- EPS-$7.27
- EBITDA$2.6B
- EBIT$1.9B
- Net income-$9.1B
Historical beat/miss
Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.
| Period | Rev. actual | Rev. est. | Rev. surprise | EPS actual | EPS est. | EPS surprise |
|---|---|---|---|---|---|---|
| Q1 2026 | $7B | $6.9B | +0.7% | $2.03 | $1.91 | +6.3% |
| Q4 2025 | $7.9B | $7.7B | +3.0% | $1.86 | $1.81 | +2.8% |
- Q1 2026+0.7%+6.3%
- Q4 2025+3.0%+2.8%
Estimate revisions
How analyst consensus estimates have changed over the past 90 days.
Revision trends appear once we have collected at least two daily snapshots for this period.
Community vs analysts
See how the TickerLeague crowd's forecast stacks up against Wall Street.
Be the first to predict
No community consensus for Gilead Sciences (GILD) Q2 2026 yet. Make a prediction to start the crowd forecast.
Analyst price target
Based on price targets from 4 analysts.
- Low
- $120.00
- Consensus
- $159.28
- Median
- $162.50
- High
- $180.00
- Current
- $129.31
- Upside
- +23.2%
Upside calculated vs most recent trading price of $129.31.
Analyst ratings
Consensus: Buy — based on 58 analyst ratings.
24-month trend
Recent analyst actions
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 21, 2026 | Leerink Partners | downgrade | Outperform | Market Perform |
| Jul 8, 2026 | Morgan Stanley | maintain | Overweight | Overweight |
| Jul 7, 2026 | Truist Securities | maintain | Buy | Buy |
| Jul 7, 2026 | RBC Capital | maintain | Sector Perform | Sector Perform |
| Jul 6, 2026 | HSBC | upgrade | Hold | Buy |
| Jul 6, 2026 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| Jun 16, 2026 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| May 20, 2026 | Maxim Group | upgrade | Hold | Buy |
| May 8, 2026 | Truist Securities | maintain | Buy | Buy |
| May 8, 2026 | RBC Capital | maintain | Sector Perform | Sector Perform |
- Jul 21, 2026Leerink PartnersMarket Perform
- Jul 8, 2026Morgan StanleyOverweight
- Jul 7, 2026Truist SecuritiesBuy
- Jul 7, 2026RBC CapitalSector Perform
- Jul 6, 2026HSBCBuy
- Jul 6, 2026Cantor FitzgeraldOverweight
- Jun 16, 2026Cantor FitzgeraldOverweight
- May 20, 2026Maxim GroupBuy
- May 8, 2026Truist SecuritiesBuy
- May 8, 2026RBC CapitalSector Perform
Frequently asked questions
Gilead Sciences (GILD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks0.93% TTM
- Dividend Profile2.49% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History5 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.